Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study

Bruce C. V. Campbell, Peter J. Mitchell, Leonid Churilov, Nawaf Yassi, Timothy J. Kleinig, Bernard Yan, Richard J. Dowling, Steven J. Bush, Helen M. Dewey, Vincent Thijs, Marion Simpson, Mark Brooks, Hamed Asadi, Teddy Y. Wu, Darshan G. Shah, Tissa Wijeratne, Timothy Ang, Ferdinand Miteff, Christopher Levi, Martin KrauseTimothy J. Harrington, Kenneth C. Faulder, Brendan S. Steinfort, Peter Bailey, Henry Rice, Laetitia de Villiers, Rebecca Scroop, Wayne Collecutt, Andrew A. Wong, Alan Coulthard, P. A. Barber, Ben McGuinness, Deborah Field, Henry Ma, Winston Chong, Ronil V. Chandra, Christopher F. Bladin, Helen Brown, Kendal Redmond, David Leggett, Geoffrey Cloud, Anoop Madan, Neil Mahant, Bill O’Brien, John Worthington, Geoffrey Parker, Patricia M. Desmond, Mark W. Parsons, Geoffrey A. Donnan, Stephen M. Davis, EXTEND-IA TNK Investigators

Research output: Contribution to journalArticlepeer-review

59 Citations (Scopus)


Background and hypothesis: Intravenous thrombolysis with alteplase remains standard care prior to thrombectomy for eligible patients within 4.5 h of ischemic stroke onset. However, alteplase only succeeds in reperfusing large vessel arterial occlusion prior to thrombectomy in a minority of patients. We hypothesized that tenecteplase is non-inferior to alteplase in achieving reperfusion at initial angiogram, when administered within 4.5 h of ischemic stroke onset, in patients planned to undergo endovascular therapy. Study design: EXTEND-IA TNK is an investigator-initiated, phase II, multicenter, prospective, randomized, open-label, blinded-endpoint non-inferiority study. Eligibility requires a diagnosis of ischemic stroke within 4.5 h of stroke onset, pre-stroke modified Rankin Scale≤3 (no upper age limit), large vessel occlusion (internal carotid, basilar, or middle cerebral artery) on multimodal computed tomography and absence of contraindications to intravenous thrombolysis. Patients are randomized to either IV alteplase (0.9 mg/kg, max 90 mg) or tenecteplase (0.25 mg/kg, max 25 mg) prior to thrombectomy. Study outcomes: The primary outcome measure is reperfusion on the initial catheter angiogram, assessed as modified treatment in cerebral infarction 2 b/3 or the absence of retrievable thrombus. Secondary outcomes include modified Rankin Scale at day 90 and favorable clinical response (reduction in National Institutes of Health Stroke Scale by ≥8 points or reaching 0–1) at day 3. Safety outcomes are death and symptomatic intracerebral hemorrhage. Trial registration: ClinicalTrials.gov NCT02388061.

Original languageEnglish
Pages (from-to)328-334
Number of pages7
JournalInternational Journal of Stroke
Issue number3
Publication statusPublished - 1 Apr 2018
Externally publishedYes


  • alteplase
  • CT perfusion
  • endovascular thrombectomy
  • intra-arterial clot retrieval
  • Ischemic stroke
  • randomized trial
  • tenecteplase
  • thrombolysis
  • tissue plasminogen activator


Dive into the research topics of 'Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study'. Together they form a unique fingerprint.

Cite this